Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for NMR and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for NMR and 80,000+ other tickers.
See exactly how NMR's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NMR and 80,000+ other tickers.
Nomura Holdings, Inc. engages in the provision of investment, financing, and related services to individual, institutional, and government clients worldwide. It operates through three segments: Wealth Management, Investment Management, and Wholesale. The Wealth Management segment offers investment consultation services. The Investment Management segment provides investment management services and investment solutions, such as establishing and managing investment trusts, discretionary investment services, as well as investment and management for investment vehicles, and for funds for…
NMR's Q2 earnings are expected to decline 9.1% y/y despite healthy equity trading, wealth management inflows and higher investment management fees.
Investors interested in Financial - Investment Bank stocks are likely familiar with Nomura Holdings (NMR) and Tradeweb Markets (TW). But which of these two stocks is more attractive to value investors?
The heavy selling pressure might have exhausted for Nomura (NMR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Velocity Bioworks successfully completes initial evaluation of LarmorBio's BioScan-NMR™ platform, generating data supporting the continued development of continuous, real-time, non-invasive bioprocess monitoring of cell size, density, viability, and phenotype within bioreactors Milestone achieved less than six months after Valion Bio secured exclusive rights to LarmorBio's next-generation NMR technology SAN ANTONIO, TX AND WALTHAM, MA / ACCESS Newswire / October 15, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company") and LarmorBio, Inc. ("LarmorBio") today announced that Velocity Bioworks, Valion's wholly owned biologics contract development and manufacturing organization ("CDMO") subsidiary, has successfully completed an initial feasibility evaluation of LarmorBio's BioScan-NMR™ platform. BioScan-NMR™ is being developed to create a new class of process analytical technology ("PAT") for biologics manufacturing.
Nomura (NYSE: NMR - Get Free Report) and Equus Total Return (NYSE: EQS - Get Free Report) are both finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation. Profitability This table compares Nomura and Equus Total